title: Clinical trials: past, current, and future for atypical Parkinsonian syndromes.
abstract: There are currently no effective Food and Drug Administration-approved treatments for atypical parkinsonian disorders such as progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, or multiple system atrophy. Previous treatment trials for these disorders were focused on symptomatic support and did not affect disease progression. Recent breakthroughs in neuropathology and pathophysiology have allowed a new understanding of these disorders and investigation into potentially disease modifying therapies. Randomized, placebo-controlled clinical trials of these disorders will be reviewed here. Suggestions for future therapeutic targets and clinical trial design (with a focus on progressive supranuclear palsy) will also be provided.
authors: Department of Neurology, University of California San Francisco, San Francisco, California.
authors: Richard M
authors: RM
authors: Tsai
authors: Department of Neurology, University of California San Francisco, San Francisco, California.
authors: Adam L
authors: AL
authors: Boxer
mesh_terms: D002986:Clinical Trials as Topic / Q000639:trends*; D006801:Humans; D019578:Multiple System Atrophy / Q000188:drug therapy*; D020734:Parkinsonian Disorders / Q000188:drug therapy*; D013494:Supranuclear Palsy, Progressive / Q000188:drug therapy*; D014481:United States